Enhanced MRI of tumors utilizing a new nitroxyl spin label contrast agent

Richard Lorne Ehman, George E. Wesbey, Kirk L. Moon, Richard D. Williams, Michael T. McNamara, William R. Couet, Thomas N. Tozer, Robert C. Brasch

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Nitroxyl spin labels have been shown to be effective in vivo contrast agents for magnetic resonance imaging (MRI) of the central nervous system, myocardium, and urinary tract. A new pyrrolidine nitroxyl contrast agent (PCA) with better resistance to in vivo metabolic inactivation than previously tested agents was studied for its potential to enhance subcutaneous neoplasms in an animal model. Twenty-two contrast enhancement trials were performed on a total of 15 animals 4-6 weeks after implantation with human renal adenocarcinoma. Spin echo imaging was performed using a .35 T animal imager before and after intravenous administration of PCA in doses ranging from 0.5 to 3 mM/kg. The intensity of tumor tissue in the images increased an average of 35% in animals receiving a dose of 3 mM/kg. The average enhancement with smaller doses was proportionately less. Tumor intensity reached a maximum within 15 min of injection. The average intensity difference between tumor and adjacent skeletal muscle more than doubled following administration of 3 mM/kg of PCA. Well-perfused tumor tissue was more intensely enhanced than adjacent poorly perfused and necrotic tissue.

Original languageEnglish (US)
Pages (from-to)89-97
Number of pages9
JournalMagnetic Resonance Imaging
Volume3
Issue number1
DOIs
StatePublished - 1985
Externally publishedYes

Fingerprint

Spin Labels
Magnetic resonance
Contrast Media
magnetic resonance
Labels
Tumors
Animals
tumors
Magnetic Resonance Imaging
Imaging techniques
animals
Tissue
Neoplasms
dosage
Neurology
myocardium
neoplasms
skeletal muscle
central nervous system
Image sensors

Keywords

  • MRI contrast media
  • MRI of tumors
  • Nitroxide spin label

ASJC Scopus subject areas

  • Biophysics
  • Clinical Biochemistry
  • Structural Biology
  • Radiology Nuclear Medicine and imaging
  • Condensed Matter Physics

Cite this

Ehman, R. L., Wesbey, G. E., Moon, K. L., Williams, R. D., McNamara, M. T., Couet, W. R., ... Brasch, R. C. (1985). Enhanced MRI of tumors utilizing a new nitroxyl spin label contrast agent. Magnetic Resonance Imaging, 3(1), 89-97. https://doi.org/10.1016/0730-725X(85)90013-X

Enhanced MRI of tumors utilizing a new nitroxyl spin label contrast agent. / Ehman, Richard Lorne; Wesbey, George E.; Moon, Kirk L.; Williams, Richard D.; McNamara, Michael T.; Couet, William R.; Tozer, Thomas N.; Brasch, Robert C.

In: Magnetic Resonance Imaging, Vol. 3, No. 1, 1985, p. 89-97.

Research output: Contribution to journalArticle

Ehman, RL, Wesbey, GE, Moon, KL, Williams, RD, McNamara, MT, Couet, WR, Tozer, TN & Brasch, RC 1985, 'Enhanced MRI of tumors utilizing a new nitroxyl spin label contrast agent', Magnetic Resonance Imaging, vol. 3, no. 1, pp. 89-97. https://doi.org/10.1016/0730-725X(85)90013-X
Ehman, Richard Lorne ; Wesbey, George E. ; Moon, Kirk L. ; Williams, Richard D. ; McNamara, Michael T. ; Couet, William R. ; Tozer, Thomas N. ; Brasch, Robert C. / Enhanced MRI of tumors utilizing a new nitroxyl spin label contrast agent. In: Magnetic Resonance Imaging. 1985 ; Vol. 3, No. 1. pp. 89-97.
@article{1ac279eb33de4c1996dfaa43a27ff5b6,
title = "Enhanced MRI of tumors utilizing a new nitroxyl spin label contrast agent",
abstract = "Nitroxyl spin labels have been shown to be effective in vivo contrast agents for magnetic resonance imaging (MRI) of the central nervous system, myocardium, and urinary tract. A new pyrrolidine nitroxyl contrast agent (PCA) with better resistance to in vivo metabolic inactivation than previously tested agents was studied for its potential to enhance subcutaneous neoplasms in an animal model. Twenty-two contrast enhancement trials were performed on a total of 15 animals 4-6 weeks after implantation with human renal adenocarcinoma. Spin echo imaging was performed using a .35 T animal imager before and after intravenous administration of PCA in doses ranging from 0.5 to 3 mM/kg. The intensity of tumor tissue in the images increased an average of 35{\%} in animals receiving a dose of 3 mM/kg. The average enhancement with smaller doses was proportionately less. Tumor intensity reached a maximum within 15 min of injection. The average intensity difference between tumor and adjacent skeletal muscle more than doubled following administration of 3 mM/kg of PCA. Well-perfused tumor tissue was more intensely enhanced than adjacent poorly perfused and necrotic tissue.",
keywords = "MRI contrast media, MRI of tumors, Nitroxide spin label",
author = "Ehman, {Richard Lorne} and Wesbey, {George E.} and Moon, {Kirk L.} and Williams, {Richard D.} and McNamara, {Michael T.} and Couet, {William R.} and Tozer, {Thomas N.} and Brasch, {Robert C.}",
year = "1985",
doi = "10.1016/0730-725X(85)90013-X",
language = "English (US)",
volume = "3",
pages = "89--97",
journal = "Magnetic Resonance Imaging",
issn = "0730-725X",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Enhanced MRI of tumors utilizing a new nitroxyl spin label contrast agent

AU - Ehman, Richard Lorne

AU - Wesbey, George E.

AU - Moon, Kirk L.

AU - Williams, Richard D.

AU - McNamara, Michael T.

AU - Couet, William R.

AU - Tozer, Thomas N.

AU - Brasch, Robert C.

PY - 1985

Y1 - 1985

N2 - Nitroxyl spin labels have been shown to be effective in vivo contrast agents for magnetic resonance imaging (MRI) of the central nervous system, myocardium, and urinary tract. A new pyrrolidine nitroxyl contrast agent (PCA) with better resistance to in vivo metabolic inactivation than previously tested agents was studied for its potential to enhance subcutaneous neoplasms in an animal model. Twenty-two contrast enhancement trials were performed on a total of 15 animals 4-6 weeks after implantation with human renal adenocarcinoma. Spin echo imaging was performed using a .35 T animal imager before and after intravenous administration of PCA in doses ranging from 0.5 to 3 mM/kg. The intensity of tumor tissue in the images increased an average of 35% in animals receiving a dose of 3 mM/kg. The average enhancement with smaller doses was proportionately less. Tumor intensity reached a maximum within 15 min of injection. The average intensity difference between tumor and adjacent skeletal muscle more than doubled following administration of 3 mM/kg of PCA. Well-perfused tumor tissue was more intensely enhanced than adjacent poorly perfused and necrotic tissue.

AB - Nitroxyl spin labels have been shown to be effective in vivo contrast agents for magnetic resonance imaging (MRI) of the central nervous system, myocardium, and urinary tract. A new pyrrolidine nitroxyl contrast agent (PCA) with better resistance to in vivo metabolic inactivation than previously tested agents was studied for its potential to enhance subcutaneous neoplasms in an animal model. Twenty-two contrast enhancement trials were performed on a total of 15 animals 4-6 weeks after implantation with human renal adenocarcinoma. Spin echo imaging was performed using a .35 T animal imager before and after intravenous administration of PCA in doses ranging from 0.5 to 3 mM/kg. The intensity of tumor tissue in the images increased an average of 35% in animals receiving a dose of 3 mM/kg. The average enhancement with smaller doses was proportionately less. Tumor intensity reached a maximum within 15 min of injection. The average intensity difference between tumor and adjacent skeletal muscle more than doubled following administration of 3 mM/kg of PCA. Well-perfused tumor tissue was more intensely enhanced than adjacent poorly perfused and necrotic tissue.

KW - MRI contrast media

KW - MRI of tumors

KW - Nitroxide spin label

UR - http://www.scopus.com/inward/record.url?scp=0021855003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021855003&partnerID=8YFLogxK

U2 - 10.1016/0730-725X(85)90013-X

DO - 10.1016/0730-725X(85)90013-X

M3 - Article

C2 - 3999941

AN - SCOPUS:0021855003

VL - 3

SP - 89

EP - 97

JO - Magnetic Resonance Imaging

JF - Magnetic Resonance Imaging

SN - 0730-725X

IS - 1

ER -